Top

Published in:

Open Access 26-12-2023 | Lymphoma | Original Article

Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins

Authors: Junquan Zeng, Yongliang Zheng, Si Dong, Ting Ding, Shouhua Zhang, Kuangfan Li, Haiyun Liu, Quangang Fang, Sheng Yuan, Yujing Wei, Jing Li, Tingting Liu

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2024

Abstract

Background

Burkitt’s lymphoma, one of the most common subtypes of pediatric malignant lymphoma, is notorious for its swift onset, aggressive proliferation, pronounced invasiveness, and marked malignancy. The therapeutic landscape for Burkitt’s lymphoma currently falls short of providing universally effective and tolerable solutions. Andrographolide, a primary active component of Andrographis paniculata, is renowned for its properties of heat-clearing, detoxification, inflammation reduction, and pain relief. It is predominantly used in treating bacterial and viral infections of the upper respiratory tract, as well as dysentery. Various reports highlight the antitumor effects of andrographolide. Yet, its specific impact and the underlying mechanism of action on Burkitt’s lymphoma remain an uncharted area of research.

Method

We employed network pharmacology to pinpoint the targets of andrographolide’s action on Burkitt’s lymphoma and the associated pathways. We then evaluated the impact of andrographolide on Burkitt’s lymphoma using both in vitro and in vivo patient-derived xenograft (PDX) models. Concurrently, we confirmed the molecular targets of andrographolide in Burkitt’s lymphoma through immunofluorescence assays.

Result

Utilizing network pharmacology, we identified 15 relevant targets, 60 interrelationships between these targets, and numerous associated signaling pathways for andrographolide’s action on Burkitt’s lymphoma. In vitro efficacy tests using High-throughput Drug Sensitivity Testing and in vivo PDX model evaluations revealed that andrographolide effectively curtailed the growth of Burkitt’s lymphoma. Moreover, we observed a increased in the expression of JUN (c-Jun) and CASP3 (Caspase 3) proteins in Burkitt’s lymphoma cells treated with andrographolide.

Conclusion

Andrographolide inhibits the growth of Burkitt’s lymphoma by inhibiting JUN and CASP3 proteins.

López C, Burkhardt B, Chan J, Leoncini L, Mbulaiteye S, Ogwang M et al (2022) Burkitt lymphoma. Nat Rev Dis Prim 8(1):78CrossRefPubMed

Crombie J, LaCasce A (2021) The treatment of Burkitt lymphoma in adults. Blood 137(6):743–750CrossRefPubMed

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRefPubMedPubMedCentral

Brady G, MacArthur GJ, Farrell PJ (2007) Epstein–Barr virus and Burkitt lymphoma. J Clin Pathol 60(12):1397–1402PubMedPubMedCentral

Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS et al (2009) Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma 9(4):307–310CrossRefPubMedPubMedCentral

Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N et al (2013) A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt’s lymphoma. Ann Oncol 24(12):3076–3081CrossRefPubMedPubMedCentral

Burgos RA, Alarcón P, Quiroga J, Manosalva C, Hancke J (2020) Andrographolide, an anti-inflammatory multitarget drug: all roads lead to cellular metabolism. Molecules 26(1):5CrossRefPubMedPubMedCentral

Peng Y, Wang Y, Tang N, Sun D, Lan Y, Yu Z et al (2018) Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res CR 37(1):248CrossRefPubMed

Yuan M, Meng W, Liao W, Lian S (2018) Andrographolide antagonizes TNF-α-induced IL-8 via inhibition of NADPH oxidase/ROS/NF-κB and Src/MAPKs/AP-1 axis in human colorectal cancer HCT116 cells. J Agric Food Chem 66(20):5139–5148CrossRefPubMed

10.

Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J et al (2010) Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer 1(8):868–876CrossRefPubMedPubMedCentral

11.

Reabroi S, Saeeng R, Boonmuen N, Kasemsuk T, Saengsawang W, Suksen K et al (2018) The anti-cancer activity of an andrographolide analogue functions through a GSK-3β-independent Wnt/β-catenin signaling pathway in colorectal cancer cells. Sci Rep 8(1):7924CrossRefPubMedPubMedCentral

12.

He Y, Mei J, Hao H, Liu F, Yi Y, Hu C et al (2023) Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer. J Cancer Res Clin Oncol 25:1–11

13.

Vogt PK (2002) Fortuitous convergences: the beginnings of JUN. Nat Rev Cancer 2(6):465–469CrossRefPubMed

14.

Schreiber M, Kolbus A, Piu F, Szabowski A, Möhle-Steinlein U, Tian J et al (1999) Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13(5):607–619CrossRefPubMedPubMedCentral

15.

Wisdom R, Johnson RS, Moore C (1999) c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. Embo J 18(1):188–197CrossRefPubMedPubMedCentral

16.

Zhang L, Sun S, Wang Y, Mo Y, Xiong F, Zhang S et al (2020) Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway. Am J Cancer Res 10(3):870–883PubMedPubMedCentral

17.

Wang S, Li H, Chen S, Wang Z, Yao Y, Chen T et al (2020) Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway. Int J Oncol 56(6):1417–1428PubMedPubMedCentral

18.

Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K et al (2010) Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata. Clin Cancer Res 16(19):4755–4768CrossRefPubMedPubMedCentral

19.

Galluzzi L, López-Soto A, Kumar S, Kroemer G (2016) Caspases connect cell-death signaling to organismal homeostasis. Immunity 44(2):221–231CrossRefPubMed

20.

Zhou M, Liu X, Li Z, Huang Q, Li F, Li CY (2018) Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. Int J Cancer 143(4):921–930CrossRefPubMedPubMedCentral

21.

Shi J, Li Y, Jia R, Fan X (2020) The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance. Int J Cancer 146(8):2078–2088CrossRefPubMed

22.

Cho SY, Kang W, Han JY, Min S, Kang J, Lee A et al (2016) An integrative approach to precision cancer medicine using patient-derived xenografts. Mol Cells 39(2):77–86CrossRefPubMedPubMedCentral

Title: Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins
Authors: Junquan Zeng
Yongliang Zheng
Si Dong
Ting Ding
Shouhua Zhang
Kuangfan Li
Haiyun Liu
Quangang Fang
Sheng Yuan
Yujing Wei
Jing Li
Tingting Liu
Publication date: 26-12-2023
Publisher: Springer Berlin Heidelberg
Keyword: Lymphoma
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2024
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-023-04626-4

EASD 2024

Springer Medicine

Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins

Abstract

Background

Method

Result

Conclusion

EASD 2024

Springer Medicine

Abstract

Background

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2024

Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients

CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms

Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults

Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study

Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study

Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy